188 related articles for article (PubMed ID: 28566743)
1. Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations.
Ayoub BM; Mowaka S; Elzanfaly ES; Ashoush N; Elmazar MM; Mousa SA
Sci Rep; 2017 May; 7(1):2583. PubMed ID: 28566743
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
Macha S; Brand T; Meinicke T; Link J; Broedl UC
Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
[TBL] [Abstract][Full Text] [Related]
3. A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers.
Dias BCL; Fachi MM; de Campos ML; Degaut FLD; Peccinini RG; Pontarolo R
Biomed Chromatogr; 2019 Nov; 33(11):e4663. PubMed ID: 31339572
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
5. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
Macha S; Jungnik A; Hohl K; Hobson D; Salsali A; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):873-9. PubMed ID: 24152604
[TBL] [Abstract][Full Text] [Related]
6. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Kim YK; Hwang JG; Park MK
Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
[TBL] [Abstract][Full Text] [Related]
7. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.
Glund S; Mattheus M; Runge F; Rose P; Friedrich C
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):355-367. PubMed ID: 28290274
[TBL] [Abstract][Full Text] [Related]
8. Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine.
van der Aart-van der Beek AB; Wessels AMA; Heerspink HJL; Touw DJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122257. PubMed ID: 32663790
[TBL] [Abstract][Full Text] [Related]
9. Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics.
Wattamwar T; Mungantiwar A; Halde S; Pandita N
Eur J Mass Spectrom (Chichester); 2020 Apr; 26(2):117-130. PubMed ID: 31575298
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
11. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats.
Kobuchi S; Matsuno M; Fukuda E; Ito Y; Sakaeda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():227-33. PubMed ID: 27304784
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
Macha S; Lang B; Pinnetti S; Broedl UC
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):973-80. PubMed ID: 25161155
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
[TBL] [Abstract][Full Text] [Related]
16. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.
Wilcox CS; Shen W; Boulton DW; Leslie BR; Griffen SC
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29440005
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study.
Shah PA; Shrivastav PS; Shah JV; George A
Biomed Chromatogr; 2019 Apr; 33(4):e4453. PubMed ID: 30517974
[TBL] [Abstract][Full Text] [Related]
18. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
19. Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Zou JJ; Bian XJ; Ding L; Zhu YB; Fan HW; Xiao DW
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(1):151-7. PubMed ID: 18069077
[TBL] [Abstract][Full Text] [Related]
20. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
